The benefits of full-scale adoption of health information technology (HIT) will be significant, leading to a higher standard of quality in the U.S. health care system, Lynne M. Kirk, MD, FACP, president of the American College of Physicians (ACP), today told a hearing of the Subcommittee on Regulations, Healthcare and Trade of the House Committee on Small Business.
Women with a recent diagnosis of cancer in one breast should have MRI screening of the opposite breast, concludes a multi-center study involving University of North Carolina at Chapel Hill researchers.
Diabetes and high blood pressure, two conditions rooted in genetics and environmental surroundings, play a much greater role than race alone in determining who is mostly likely to develop heart failure, according to the latest study from cardiologists at Johns Hopkins. Each year, nearly 300,000 Americans die from heart failure.
If you want the best technology available to relieve blocked blood flow to the heart, the choice is a drug-eluting stent. And you are most likely to obtain the drug-eluting stent for reasons that have nothing to do with your medical condition, a new Mayo Clinic study shows.
In an era of increasing death and illness from heart and blood vessel disease — which also can impair kidney function — Mayo Clinic researchers have designed two promising new cardiovascular treatment approaches.
An herbal medicinal substance, Crataegus Extract WS?1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented today at the American College of Cardiology?s 56th Annual Scientific Session.
Researchers today reported that an investigational anti-hypertensive therapy may perform better in controlling blood pressure than standard treatments for patients undergoing heart surgery, during a presentation at the American College of Cardiology?s 56th Annual Scientific Session.
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Some day, heart attack survivors might have a patch of laboratory-grown muscle placed in their heart, to replace areas that died during their attack.
New Columbia University Medical Center research suggests a genomic test may provide detailed information on how well a transplanted heart is performing.